Qingkun Yang

Qingkun Yang

Auto-generated profile, based on publicly available information

Qingkun Yang

College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
MLMaochen Li
Maochen Li
HWHan Wang
Han Wang
LTLili Tian
Lili Tian
ZPZehan Pang
Zehan Pang
QYQingkun Yang
Qingkun Yang
HFHuahao Fan
Huahao Fan
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) vaccines. Viral vector vaccines, protein subunit vaccines, and mRNA vaccines may induce additional cellular or humoral immune regulations, including Th cell responses and germinal center responses, and form relevant memory cells, greatly improving their efficiency. However, some viral vector or mRNA vaccines may be associated with complications like thrombocytopenia and myocarditis, raising concerns about the safety of these COVID-19 vaccines. Here, we systemically assess the safety and efficacy of COVID-19 vaccines, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients. Based on the current analysis, governments and relevant agencies are recommended to continue to advance the vaccine immunization process. Simultaneously, special attention should be paid to the health status of the vaccines, timely treatment of complications, vaccine development, and ensuring the lives and health of patients. In addition, available measures such as mix-and-match vaccination, developing new vaccines like nanoparticle vaccines, and optimizing immune adjuvant to improve vaccine safety and efficacy could be considered.

1 November 2025 in Journal of Catalysis
Verified
Journal Article
Closed access
QYQingkun Yang
Qingkun Yang
YCYue Chi
Yue Chi
JGJitong Gong
Jitong Gong
HMHongliang Mu
Hongliang Mu
YZYuxing Zhang
Yuxing Zhang
ZJZhongbao Jian
Zhongbao Jian